echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Boehringer Ingelheim's new drug BI 425809 for schizophrenia received clinical approval

    Boehringer Ingelheim's new drug BI 425809 for schizophrenia received clinical approval

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 24, the official website of CDE showed that Boehringer Ingelheim's new drug BI 425809 has been approved for clinical use by default and is intended to be used for the treatment of cognitive symptoms of schizophrenia.


    The abnormality of the glutamatergic pathway caused by the low function of the N-methyl-D-aspartate receptor is the pathological cause of the onset of schizophrenia and Alzheimer's disease.


    In March 2021, the results of a Phase II (NCT02832037) study of BI 425809 in the treatment of schizophrenia were published in The Lancet·Psychiatry.


    From April 25, 2018 to October 4, 2019, a total of 509 patients received treatment (BI 425809 2 mg, n=85; 5 mg, n=84; 10 mg, n=85; 25 mg, n=85 ; Placebo, n=170), 444 patients (87%) completed 12 weeks of treatment.


    The incidence of adverse reactions in each group was similar, namely: BI 425809 2 mg (59%), 5 mg (52%), 10 mg (41%), 25 mg (42%), and placebo (44%).


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.